MIST: Rega Tumbas Perusahaan milestonepharma.com

Milestone Pharmaceuticals (MIST) management is disciplined in developing cardiology treatments, focusing on key medical targets. The business relies on a diversified cold chain logistics network, ensuring high margins and supply reliability. Stability is guaranteed by a neutral geopolitical status and operations within Western medical clusters. The current enterprise value stands at 57.28, which clearly demonstrates the market trend of the share price in the chart below.

This metric combines market capitalization with net debt to determine the total cost of a full acquisition of Milestone Pharmaceuticals (MIST) assets, accounting for liquidity. An analysis of the enterprise value allows for an assessment of the issuer's financial stability, as its business model—characterized by extensive outsourcing of clinical trials—renders the company's final valuation sensitive to the operational risks of third-party contractors.